Aernoud Fiolet

133 Colchicine in Patients with Chronic Coronary Disease magnitude of benefit of low-dose colchicine in the LoDoCo2 trial is consistent with that shown in previous trials of antiinflammatory therapy and in previous trials of other secondary prevention therapies, including lipid-lowering, blood pressure–lowering, and antithrombotic therapies, and a benefit was observed in the patients who were already receiving therapy with these agents. 1,3,16-18 Furthermore, the benefits emerged early and continued to accrue throughout the trial, with no suggestion of attenuation of benefit during up to 5 years of treatment. The LoDoCo2 trial has several limitations. The percentage of women in the trial was lower than would be expected given the percentage of women with chronic coronary disease in the general population. We did not collect blood-pressure or lipid levels at baseline or during the trial, andwe cannot report outcomes according to risk-factor control. We did not routinely measure C-reactive protein levels or other laboratory indicators of inflammation at baseline, and we cannot explore the effects of treatment according to inflammatory state at baseline. However, the effects of treatments were consistent across the majority of clinical subgroups examined. The results of our trial show that among patients with chronic coronary disease, most of whom were already receiving proven secondary prevention therapies, the occurrence of cardiovascular events was significantly lower with low-dose colchicine than with placebo. FUNDING, DISCLOSURES AND ACKNOWLEDGEMENTS Supported by the National Health Medical Research Council of Australia, a grant from the Sir Charles Gairdner Research Advisory Committee, the Withering Foundation the Netherlands, the Netherlands Heart Foundation, the Netherlands Organization for Health Research and Development, and a consortium of Teva, Disphar, and Tiofarma in the Netherlands. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org . Dr. Mosterd reports receiving grant support from Novartis, lecture fees from Amarin, advisory board fees from Amgen and Boehringer Ingelheim, and fees for serving as national lead investigator from BMS, MSD, and Pfizer; Dr. Eikelboom, receiving grant support, paid to his institution, and honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Eli Lilly,